This is a preprint.
Outdoor Nighttime Light Exposure (Light Pollution) is Associated with Alzheimer's Disease
- PMID: 38405987
- PMCID: PMC10889016
- DOI: 10.1101/2024.02.14.24302831
Outdoor Nighttime Light Exposure (Light Pollution) is Associated with Alzheimer's Disease
Update in
-
Outdoor nighttime light exposure (light pollution) is associated with Alzheimer's disease.Front Neurosci. 2024 Sep 6;18:1378498. doi: 10.3389/fnins.2024.1378498. eCollection 2024. Front Neurosci. 2024. PMID: 39308948 Free PMC article.
Abstract
Alzheimer's disease (AD) prevalence has increased in the last century which can be attributed to increased lifespan, but environment is also important. This study evaluated the relationship between outdoor nighttime light exposure and AD prevalence in the United States. Higher outdoor nighttime light was associated with higher prevalence of AD. While atrial fibrillation, diabetes, hyperlipidemia, hypertension, and stroke were associated more strongly with AD prevalence than nighttime light intensity, nighttime light was more strongly associated with AD prevalence than alcohol abuse, chronic kidney disease, depression, heart failure, and obesity. Startlingly, nighttime light exposure more strongly associated with AD prevalence in those under the age of 65 than any other disease factor examined. These data indicate a need to investigate how nighttime light exposure influences AD pathogenesis.
Figures
Similar articles
-
Outdoor nighttime light exposure (light pollution) is associated with Alzheimer's disease.Front Neurosci. 2024 Sep 6;18:1378498. doi: 10.3389/fnins.2024.1378498. eCollection 2024. Front Neurosci. 2024. PMID: 39308948 Free PMC article.
-
Outdoor Artificial Nighttime Light and Use of Hypnotic Medications in Older Adults: A Population-Based Cohort Study.J Clin Sleep Med. 2018 Nov 15;14(11):1903-1910. doi: 10.5664/jcsm.7490. J Clin Sleep Med. 2018. PMID: 30373695 Free PMC article.
-
The Effect of Type 2 Diabetes Mellitus on Neuropsychological Symptoms in Chinese Early Alzheimer's Disease Population.Neuropsychiatr Dis Treat. 2020 Mar 26;16:829-836. doi: 10.2147/NDT.S240529. eCollection 2020. Neuropsychiatr Dis Treat. 2020. PMID: 32273709 Free PMC article.
-
Ginsenoside Rg1, lights up the way for the potential prevention of Alzheimer's disease due to its therapeutic effects on the drug-controllable risk factors of Alzheimer's disease.J Ethnopharmacol. 2024 Jan 10;318(Pt B):116955. doi: 10.1016/j.jep.2023.116955. Epub 2023 Aug 1. J Ethnopharmacol. 2024. PMID: 37536646 Review.
-
Atrial fibrillation and Alzheimer's disease: A conundrum.Eur J Clin Invest. 2021 Jul;51(7):e13451. doi: 10.1111/eci.13451. Epub 2021 May 12. Eur J Clin Invest. 2021. PMID: 33219514 Review.
References
-
- Ahmadi-Abhari S., Guzman-Castillo M., Bandosz P., Shipley M. J., Muniz-Terrera G., Singh-Manoux A., Kivimaki M., Steptoe A., Capewell S., O’Flaherty M., and Brunner E. J.. 2017. ‘Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study’, BMJ, 358: j2856. - PMC - PubMed
-
- Al-Kuraishy H. M., Al-Gareeb A. I., Alsayegh A. A., Hakami Z. H., Khamjan N. A., Saad H. M., Batiha G. E., and De Waard M.. 2023. ‘A Potential Link Between Visceral Obesity and Risk of Alzheimer’s Disease’, Neurochem Res, 48: 745–66. - PubMed
-
- Alford S., Patel D., Perakakis N., and Mantzoros C. S.. 2018. ‘Obesity as a risk factor for Alzheimer’s disease: weighing the evidence’, Obes Rev, 19: 269–80. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources